Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.
Also called NCT02220907
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 153 participants
- Sponsor
- Registry
-
NCT02220907
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02220907. Allocation not applicable; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-08-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Teneligliptin/Canagliflozin
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02220907- Content hash
d43f952347821b4f449e5da60e826ec0b70c22a1cadb29cd5c1e1d7c1ac6de95